Published Online
on September 27, 2004

A more recent version of this article appeared on November 1, 2004

This Article Full Text (PDF) All Versions of this Article: 44/5/595    most recent 01.HYP.0000145180.38707.84v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bidani, A. K. Articles by Griffin, K. A. Search for Related Content PubMed PubMed Citation Articles by Bidani, A. K. Articles by Griffin, K. A. Pubmed/NCBI databases Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Kidney Diseases Related Collections ACE/Angiotension receptors Animal models of human disease Type 1 diabetes Type 2 diabetes Clinical Studies Other Vascular biology

Submitted on August 5, 2004
Revised on August 11, 2004

Pathophysiology of Hypertensive Renal Damage. Implications for Therapy

Anil K. Bidani^* and Karen A. Griffin

From Loyola University Medical Center and Edward Hines Jr. VA Hospital, Maywood, Ill.

^* To whom correspondence should be addressed. E-mail: abidani{at}lumc.edu.

Abstract--Unlike the majority of patients with uncomplicated hypertension in whom minimal renal damage develops in the absence of severe blood pressure (BP) elevations, patients with diabetic and nondiabetic chronic kidney disease (CKD) exhibit an increased vulnerability to even moderate BP elevations. Investigations in experimental animal models have revealed that this enhanced susceptibility is a consequence of an impairment of the renal autoregulatory mechanisms that normally attenuate the transmission of elevated systemic pressures to the glomeruli in uncomplicated hypertension. The markedly lower BP threshold for renal damage and the steeper slope of relationship between BP and renal damage in such states necessitates that BP be lowered into the normotensive range to prevent progressive renal damage. When BP is accurately measured using radiotelemetry in animal models, the renal protection provided by renin-angiotensin system (RAS) blockade is proportional to the BP reduction with little evidence of BP-independent protection. A critical evaluation of the clinical data also suggests that the BP-independent renoprotection by RAS blockade has been overemphasized and that achieving lower BP targets is more important than the selection of antihypertensive regimens. However, achievement of such BP goals is difficult in CKD patients without aggressive diuresis, because of their proclivity for salt retention. The effectiveness of RAS blockers in lowering BP in patients who have been adequately treated with diuretics, along with their potassium-sparing and magnesium-sparing effects, provides a more compelling rationale for the use of RAS blockade in the treatment of CKD patients than any putative BP-independent renoprotective superiority.

Key words: nephrosclerosis • autoregulation • telemetry • antihypertensive agents • renin-angiotensin system • glomerulosclerosis

This article has been cited by other articles:

				Z. Guan, J. S. Pollock, A. K. Cook, J. L. Hobbs, and E. W. Inscho Effect of Epithelial Sodium Channel Blockade on the Myogenic Response of Rat Juxtamedullary Afferent Arterioles Hypertension, November 1, 2009; 54(5): 1062 - 1069. [Abstract] [Full Text] [PDF]

				K. L. Siu, B. Sung, W. A. Cupples, L. C. Moore, and K. H. Chon Detection of low-frequency oscillations in renal blood flow Am J Physiol Renal Physiol, July 1, 2009; 297(1): F155 - F162. [Abstract] [Full Text] [PDF]

				C. S. Wilcox and A. Pearlman Chemistry and Antihypertensive Effects of Tempol and Other Nitroxides Pharmacol. Rev., December 1, 2008; 60(4): 418 - 469. [Abstract] [Full Text] [PDF]

				B. Klanke, N. Cordasic, A. Hartner, R. E. Schmieder, R. Veelken, and K. F. Hilgers Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3456 - 3463. [Abstract] [Full Text] [PDF]

				H. A. Drummond, N. L. Jernigan, and S. C. Grifoni Sensing Tension: Epithelial Sodium Channel/Acid-Sensing Ion Channel Proteins in Cardiovascular Homeostasis Hypertension, May 1, 2008; 51(5): 1265 - 1271. [Full Text] [PDF]

				H. A. Drummond, S. C. Grifoni, and N. L. Jernigan A New Trick for an Old Dogma: ENaC Proteins as Mechanotransducers in Vascular Smooth Muscle Physiology, February 1, 2008; 23(1): 23 - 31. [Abstract] [Full Text] [PDF]

				E. Pimenta, K. K. Gaddam, M. N. Pratt-Ubunama, M. K. Nishizaka, I. Aban, S. Oparil, and D. A. Calhoun Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension Hypertension, February 1, 2008; 51(2): 339 - 344. [Abstract] [Full Text] [PDF]

				S. Steigerwalt Management of Hypertension in Diabetic Patients With Chronic Kidney Disease Diabetes Spectr, January 1, 2008; 21(1): 30 - 36. [Abstract] [Full Text] [PDF]

				N. L. Jernigan, B. LaMarca, J. Speed, L. Galmiche, J. P. Granger, and H. A. Drummond Dietary salt enhances benzamil-sensitive component of myogenic constriction in mesenteric arteries Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H409 - H420. [Abstract] [Full Text] [PDF]

				N. D. Vaziri, Y. Bai, Z. Ni, Y. Quiroz, R. Pandian, and B. Rodriguez-Iturbe Intra-Renal Angiotensin II/AT1 Receptor, Oxidative Stress, Inflammation, and Progressive Injury in Renal Mass Reduction J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 85 - 93. [Abstract] [Full Text] [PDF]

				M. E. Safar Mechanism(s) of Systolic Blood Pressure Reduction and Drug Therapy in Hypertension Hypertension, July 1, 2007; 50(1): 167 - 171. [Full Text] [PDF]

				R. Dechend, E. Shagdarsuren, P. Gratze, A. Fiebeler, B. Pilz, S. Meiners, W. Derer, D. L Feldman, R. Webb, and D. N Muller Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 81 - 84. [Abstract] [PDF]

				N. de las Heras, M. Ruiz-Ortega, M. Ruperez, D. Sanz-Rosa, M. Miana, P. Aragoncillo, S. Mezzano, V. Lahera, J. Egido, and V. Cachofeiro Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 192 - 200. [Abstract] [PDF]

				K. A. Griffin and A. K. Bidani Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1054 - 1065. [Abstract] [Full Text] [PDF]

				A. Hartner, M. Porst, B. Klanke, N. Cordasic, R. Veelken, and K. F. Hilgers Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1778 - 1785. [Abstract] [Full Text] [PDF]

				S. A. Bahous, A. Stephan, J. Blacher, and M. E. Safar Aortic Stiffness, Living Donors, and Renal Transplantation Hypertension, February 1, 2006; 47(2): 216 - 221. [Abstract] [Full Text] [PDF]

				R. J. Johnson, M. S. Segal, T. Srinivas, A. Ejaz, W. Mu, C. Roncal, L. G. Sanchez-Lozada, M. Gersch, B. Rodriguez-Iturbe, D.-H. Kang, et al. Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link? J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1909 - 1919. [Abstract] [Full Text] [PDF]